219 related articles for article (PubMed ID: 36508915)
1. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
[TBL] [Abstract][Full Text] [Related]
2. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
[TBL] [Abstract][Full Text] [Related]
3. A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs).
Singh GK; Mitra B; Arora S; Akhoon N; Verma R; Sharma P; Mitra D
Int J Dermatol; 2021 May; 60(5):579-588. PubMed ID: 33454956
[TBL] [Abstract][Full Text] [Related]
4. Severe Cutaneous Adverse Reactions: A Single-Center Retrospective Study of 173 Patients in China.
Xu Z; Shen J; Yang Y; Yuan R; Xiang LF; Zhang C
Ann Dermatol; 2019 Oct; 31(5):545-554. PubMed ID: 33911647
[TBL] [Abstract][Full Text] [Related]
5. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
Owen CE; Jones JM
Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
[TBL] [Abstract][Full Text] [Related]
6. [The major SCAR syndromes].
Piérard GE; Lesuisse M; Piérard-Franchimont C
Rev Med Liege; 2017 Oct; 72(10):444-447. PubMed ID: 29058836
[TBL] [Abstract][Full Text] [Related]
7. Key factors predicting the in-hospital mortality of patients with severe cutaneous adverse reactions in Thailand.
Chuenboonngarm N; Puaratanaarunkon T; Washrawirul C; Triwatcharikorn J; Chancheewa B; Theerawattanawit C; Chongpison Y; Rerknimitr P; Klaewsongkram J
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1881-1890. PubMed ID: 37212641
[TBL] [Abstract][Full Text] [Related]
8. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
[TBL] [Abstract][Full Text] [Related]
9. Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature.
van Hattem S; Beerthuizen GI; Kardaun SH
Br J Dermatol; 2014 Dec; 171(6):1539-45. PubMed ID: 24888401
[TBL] [Abstract][Full Text] [Related]
10. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.
Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM
Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).
Torres-Navarro I; de Unamuno-Bustos B; Botella-Estrada R
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):607-614. PubMed ID: 32846030
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan.
Huang YS; Wu CY; Chang TT; Peng CY; Lo GH; Hsu CW; Hu CT; Huang YH
Liver Int; 2021 Nov; 41(11):2671-2680. PubMed ID: 34153177
[TBL] [Abstract][Full Text] [Related]
13. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
Godfrey H; Jedlowski P; Thiede R
Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
[TBL] [Abstract][Full Text] [Related]
14. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
Dibek Misirlioglu E; Guvenir H; Bahceci S; Haktanir Abul M; Can D; Usta Guc BE; Erkocoğlu M; Toyran M; Nacaroglu HT; Civelek E; Buyuktiryaki B; Ginis T; Orhan F; Kocabas CN
J Allergy Clin Immunol Pract; 2017; 5(3):757-763. PubMed ID: 28351788
[TBL] [Abstract][Full Text] [Related]
15. An observational study of severe cutaneous adverse reactions at a tertiary care teaching hospital.
Lekshmipriya K; Pradeesh A; Vasudevan B; Dash M; Sood A; Gera V
Med J Armed Forces India; 2023 Dec; 79(Suppl 1):S209-S216. PubMed ID: 38144617
[TBL] [Abstract][Full Text] [Related]
16. Severe cutaneous adverse reactions related to systemic antibiotics.
Lin YF; Yang CH; Sindy H; Lin JY; Rosaline Hui CY; Tsai YC; Wu TS; Huang CT; Kao KC; Hu HC; Chiu CH; Hung SI; Chung WH
Clin Infect Dis; 2014 May; 58(10):1377-85. PubMed ID: 24599767
[TBL] [Abstract][Full Text] [Related]
17. Paracetamol (Acetaminophen)-associated SJS, TEN, AGEP, and DRESS Syndromes - A Narrative Review.
Pakkir Maideen NM; Barakat IR; Jumale AH
Curr Drug Saf; 2024; 19(2):218-223. PubMed ID: 37151075
[TBL] [Abstract][Full Text] [Related]
18. Treatments for Severe Cutaneous Adverse Reactions.
Cho YT; Chu CY
J Immunol Res; 2017; 2017():1503709. PubMed ID: 29445753
[TBL] [Abstract][Full Text] [Related]
19. Adverse cutaneous drug eruptions: current understanding.
Hoetzenecker W; Nägeli M; Mehra ET; Jensen AN; Saulite I; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
Semin Immunopathol; 2016 Jan; 38(1):75-86. PubMed ID: 26553194
[TBL] [Abstract][Full Text] [Related]
20. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?
Bouvresse S; Valeyrie-Allanore L; Ortonne N; Konstantinou MP; Kardaun SH; Bagot M; Wolkenstein P; Roujeau JC
Orphanet J Rare Dis; 2012 Sep; 7():72. PubMed ID: 23009177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
